367 results on '"A. Arlt"'
Search Results
2. Biochemical control with dose reduction in chronic glucocorticoid therapy over 4 years: A phase III extension study of Chronocort (Efmody) in the treatment of Congenital Adrenal Hyperplasia (CAH)
3. Combined [18F]Fluorodeoxyglucose PET and [123I]Iodometomidate-SPECT for diagnostic evaluation of indeterminate adrenal neoplasias - The prospective cross-sectional diagnostic test performance study FAMIAN
4. The differential impact of oral classic and 11-oxygenated androgen precursor administration on downstream androgen metabolism and insulin sensitivity in women with polycystic ovary syndrome
5. Primary unilateral macronodular adrenal hyperplasia with concomitant glucocorticoid and androgen excess and KDM1A inactivation
6. CHAMPAIN study: Initial results from a phase II study of efficacy, safety and tolerability of modified-release hydrocortisones: Chronocort® (Efmody®) versus Plenadren®, in primary adrenal insufficiency
7. Morning cortisol levels in patients with established primary adrenal insufficiency
8. [11C]metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: A prospective, within-patient trial
9. Impact of coronavirus disease 2019 on patients with primary adrenal insufficiency: a cross-sectional study
10. 'Pseudo-failure' of adrenal vein sampling due to cortisol co-secretion by KCNJ5-mutant adenoma, and prediction of complete clinical success by urine hybrid steroid assay
11. Switching patients with Congenital Adrenal Hyperplasia to Modified release hydrocortisone capsules: relative bioavailability and disease control
12. Machine learning-based steroid metabolome analysis reveals three distinct subtypes of polycystic ovary syndrome and implicates 11-oxygenated androgens as major drivers of metabolic risk
13. 'Pseudo-failure' of adrenal vein sampling due to cortisol co-secretion by KCNJ5-mutant adenoma, and prediction of complete clinical success by urine hybrid steroid assay
14. Switching patients with Congenital Adrenal Hyperplasia to Modified release hydrocortisone capsules: relative bioavailability and disease control
15. Machine learning-based steroid metabolome analysis reveals three distinct subtypes of polycystic ovary syndrome and implicates 11-oxygenated androgens as major drivers of metabolic risk
16. Impact of COVID-19 on patients with primary adrenal insufficiency: a cross-sectional study
17. Interventions for preventing adrenal crisis - behavioural insights
18. Steroid and global metabolome in benign adrenal tumours with mild autonomous cortisol secretion: analysis by mass spectrometry and machine learning to understand metabolic risk
19. Incidence of COVID-19 in People with Primary Adrenal Insufficiency in the UK and Reported Self-Management - A prospective study
20. Complete clinical cure of primary aldosteronism (PA) is predictable and sustained for at least two years
21. Phaeochromocytomas Most Commonly Present As Adrenal Incidentalomas - A Large Tertiary Centre Experience
22. Simulation via Instant Messaging - Birmingham Advance helps to narrow the gap of knowledge and expectations between clinicians and women with polycystic ovary syndrome: A SIMBA-PCOS mixed-method study
23. Comparison of prednisolone and modified-release hydrocortisone capsules in the treatment of congenital adrenal hyperplasia: dose and disease control
24. Normothermic machine liver perfusion as a tool to study human androgen metabolism
25. A case of unilateral post-COVID-19 adrenal haemorrhage and follow-up during pregnancies
26. Comparison of prednisolone and modified-release hydrocortisone capsules in the treatment of congenital adrenal hyperplasia: dose and disease control
27. Incidence of COVID-19 in People with Primary Adrenal Insufficiency in the UK and Reported Self-Management - A prospective study
28. Complete clinical cure of primary aldosteronism (PA) is predictable and sustained for at least two years
29. Simulation via Instant Messaging - Birmingham Advance helps to narrow the gap of knowledge and expectations between clinicians and women with polycystic ovary syndrome: A SIMBA-PCOS mixed-method study
30. Interventions for preventing adrenal crisis - behavioural insights
31. Phaeochromocytomas Most Commonly Present As Adrenal Incidentalomas - A Large Tertiary Centre Experience
32. Steroid and global metabolome in benign adrenal tumours with mild autonomous cortisol secretion: analysis by mass spectrometry and machine learning to understand metabolic risk
33. Normothermic machine liver perfusion as a tool to study human androgen metabolism
34. Resistance to thyroid hormone alpha: molecular, biochemical and physiological approach to diagnosis and therapy
35. Combining steroid and global metabolome profiling by mass spectrometry with machine learning to investigate metabolic risk in benign adrenal tumours with mild autonomous cortisol secretion
36. Fertility in congenital adrenal hyperplasia (CAH) patients on modified release hydrocortisone capsules (MRHC, Efmody)
37. Improved biochemical control with modified-release hydrocortisone overturns the impaired fludrocortisone effect in salt-wasting CAH patients
38. Simulation via instant messaging − birmingham advance (SIMBA) as a tool to bridge gaps in clinical knowledge and expectations between physicians and patients with polycystic ovary syndrome
39. Blue Morpho: An international survey investigating differences in emotional and psychosexual wellbeing by ethnicity and birthplace in women with polycystic ovary syndrome
40. Altered steroid metabolism in patients following severe trauma: the golden hour study
41. SIMBA for Students: teaching preclinical medical and pharmacy students endocrinology through online simulation - a pilot study
42. Multiplex serum steroid profiling using liquid chromatography mass spectrometry with post column infusion ammonium fluoride
43. The biochemical investigation of PCOS: a UK wide survey of laboratory practice
44. A systematic review and meta-analysis assessing psychosexual wellbeing in people with polycystic ovary syndrome
45. PCOS pearls - findings from the qualitative study assessing the lived experience of people with polycystic ovary syndrome
46. Global impact of PCOS awareness month: challenges and opportunities
47. Perceptions and experiences of women with polycystic ovary syndrome- a systematic review
48. Urinary steroid metabolomics for adrenocortical cancer diagnosis. Comparison of gas chromatography mass spectrometry to liquid chromatography mass spectrometry
49. Modified release hydrocortisone capsules (MRHC, Efmody) improve control of congenital adrenal hyperplasia (CAH) on a lower glucocorticoid dose than standard treatment
50. PCOS SEVa: High prevalence anxiety and body dysmorphia in women with PCOS attending specialist care in the UK and India
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.